News
Jan 2022
LiGalli raises €6.6 million in Series B
The LiGalli press release can be found here.
Dec 2021
Development partner Demcon published an article on LiGalli in their internal Demcon Investment newsletter
Read the article here.
Sept 2021
LiGalli receives the International Life Sciences Award 2021
Read the article here.
Apr 2021
The basic MedRing patent is granted in China
Feb 2021
Stunning results LiGalli first in human study
See press release here.
Sept 2020
The MedRing Alpha 1.0 is ready
The first in-human trials will start shortly.
March 2020
The basic MedRing patent is granted
First in the EU, later also in the US
Feb 2020
The MedRing functional model is ready
Watch the video on the page “How it works.”
Dec 2019
The Dutch Government awards LiGalli the MIT subsidy
We look forward to working with our new partner Gimix.
What's new
If you had to guess, which is more common in women—diabetes or endometriosis? It’s a trick question. They actually affect women equally. However, endometriosis receives $1 of research funding for every $200 invested in diabetes.
While there may be various explanations for this discrepancy, there’s a long pattern of health care providers, venture capitalists, and science…
Get in touch
Koninginnegracht 33
2514 AC The Hague
The Netherlands